Physician profile
Scott Nesland
NPI 1467067140
$3,901.72
in general payments reported to CMS, 2019-2025
26 companies · $902 in 2025
The $902 reported for 2025 was more than what 78% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $814 · 2022: $1,239 · 2023: $308 · 2024: $639 · 2025: $902.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,849.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,848.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $828.20 | 2021-2025 | Airsupra, Breztri |
| Abbvie INC. | $722.10 | 2021-2025 | |
| Novo Nordisk INC | $539.94 | 2021-2025 | Rybelsus, Ozempic |
| Pfizer INC. | $328.21 | 2021-2024 | |
| Glaxosmithkline, LLC. | $228.36 | 2021-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Novartis Pharmaceuticals Corporation | $171.71 | 2021-2025 | |
| Ars Pharmaceuticals Operations, INC. | $121.25 | 2025 | Neffy |
| Exact Sciences Corporation | $114.92 | 2023-2024 | Cologuard Collection Kit |
| Sunovion Pharmaceuticals INC. | $100.79 | 2021 | |
| Dexcom, INC. | $97.30 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $75.19 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $73.17 | 2021 | |
| Lilly USA, LLC | $73.16 | 2021-2025 | Zepbound, Mounjaro |
| Merck Sharp & Dohme LLC | $69.59 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $64.06 | 2021-2024 | Tradjenta, Jardiance |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $50.19 | 2021-2025 | Xifaxan |
| Amgen INC. | $44.40 | 2022-2025 | Evenity |
| Mylan Specialty L.P. | $38.31 | 2021-2024 | Yupelri |
| Daiichi Sankyo INC. | $34.92 | 2021 | |
| Xeris Pharmaceuticals, INC. | $24.97 | 2022 | |
| Alkermes, INC. | $22.04 | 2023 | Aristada, Lybalvi |
| Nestle Healthcare Nutrition INC. | $18.04 | 2022 | |
| Sanofi Pasteur INC. | $16.90 | 2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $16.85 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $15.40 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.75 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Nesland listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.